Previous 10 | Next 10 |
BOSTON , Dec. 20, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced top-line dat...
BOSTON , Nov. 19, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy...
Stealth BioTherapeutics Corp. (MITO) Q3 2019 Results Conference Call November 14, 2019 08:30 AM ET Company Participants Henry Hess - Henry Hess Reenie McCarthy - CEO Rob Weiskopf - CFO Jim Carr - Chief Clinical Development Officer Brian Blakey - Chief Business Officer Conf...
Image source: The Motley Fool. Stealth BioTherapeutics Corp (NASDAQ: MITO) Q3 2019 Earnings Call Nov 14, 2019 , 8:30 a.m. ET Operator Continue reading
Stealth BioTherapeutics (NASDAQ: MITO ): Q3 GAAP EPS of -$0.04 in-line. More news on: Stealth BioTherapeutics Corp, Earnings news and commentary, Healthcare stocks news, Read more ...
BOSTON , Nov. 14, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported finan...
Purgatory is hell with hope .” - Philip José Farmer Today we take an in-depth look at this " Tier 4 " biotech concern and "Busted IPO". The company recently inked a developmental deal with Alexion Pharmaceuticals ( ALXN ) , which buoyed the beaten-down shares following t...
BOSTON , Nov. 11, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will rep...
Thinly traded micro cap Stealth BioTherapeutics ( MITO +2.2% ) perks up, albeit on volume of only 5,300 shares, on the heels of new data from the open-label extension portion of its Phase 2/3 TAZPOWER study evaluating Fast Track-tagged elamipretide in patients with a rare inherited dis...
BOSTON , Oct. 17, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of ne...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...